Compare Mongodb Inc (MDB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Tango Therapeutics Inc. — how do they compare? Mongodb Inc trades at $351 (market cap $30.05B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Mongodb Inc is far larger — about 8× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 3,027,814). Which is the better fit depends on your goals — on Pluang, investors hold Mongodb Inc for 46 Days and Tango Therapeutics Inc. for 0 Days on average.
| MDB | TNGX | |
|---|---|---|
Market Cap | $30.05B | $3.75B |
Volume | 3,027,814 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $472.29 | $32.90 |
52-Week Low | $225.95 | $7.50 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $27.67B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $356.29, down 6.56% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly EPS beats, with Q3 2026 results pending. Revenue has grown from $874 million in 2022 to $2.01 billion in 2025, though net losses persist, narrowing to -$129 million in 2025. Recent news highlights AI product launches and a CEO transition, with investor sentiment mixed following a sharp sell-off.
The outlook is cautiously optimistic, with a consensus price target of $456.76 implying 28% upside. Key opportunities include raised long-term revenue targets exceeding 20% growth and AI-driven product expansion. Risks involve continued net losses, high valuation multiples, and execution challenges amid leadership changes. Analyst consensus is strongly bullish with 80% buy ratings, but stock volatility may persist near-term.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
